Omeros Corporation $OMER Shares Acquired by Bank of Montreal Can

Bank of Montreal Can increased its stake in shares of Omeros Corporation (NASDAQ:OMER) by 1.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 571,095 shares of the biopharmaceutical company’s stock after purchasing an additional 8,000 shares during the quarter. Bank of Montreal Can’s holdings in Omeros were worth $1,713,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Omeros by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock worth $26,610,000 after buying an additional 95,599 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock worth $1,242,000 after acquiring an additional 3,321 shares during the period. Wellington Management Group LLP purchased a new position in Omeros during the first quarter worth about $1,118,000. Nuveen LLC purchased a new position in Omeros during the first quarter worth about $938,000. Finally, Invesco Ltd. lifted its position in Omeros by 169.1% in the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after purchasing an additional 54,696 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. HC Wainwright upped their price objective on Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $33.67.

Omeros Stock Down 8.9%

Shares of OMER stock opened at $6.28 on Friday. The stock has a market cap of $427.39 million, a P/E ratio of -2.98 and a beta of 2.40. Omeros Corporation has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The business has a fifty day simple moving average of $5.71 and a 200-day simple moving average of $4.59.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.24. On average, sell-side analysts anticipate that Omeros Corporation will post -3.09 earnings per share for the current year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.